Biocept, Inc.
Biocept, Inc. (BIOC) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
bioc · stock forecast · 3 analysts (3M) · FMP · updated Apr 25, 2025
Analyst Rating & Consensus
Based on 3 Wall Street analysts in the past 3 months
Hold
3 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $0.05
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $0.05 | ↑ 0.00% |
1-day model range: $0.05–$0.06. Peak: $0.06 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · BIOC · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2023-04-14 | Maxim Group | Downgrade ↓ | Buy→Hold |
| 2020-11-25 | Feltl & Co. | Upgrade ↑ | Hold→Buy |
| 2020-11-25 | Benchmark | Downgrade ↓ | Buy→Hold |
| 2020-11-25 | Benchmark | Maintains | Buy→Buy |
| 2016-11-10 | Feltl & Co. | Upgrade ↑ | Hold→Buy |
| 2013-01-31 | Benchmark | Downgrade ↓ | Buy→Hold |
| 2012-10-18 | Benchmark | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Biocept, Inc. (BIOC) stock. Of the recent 7 rating actions, 2 were upgrades and 3 were downgrades. 3 analysts currently cover BIOC.
Analyst Recommendation Trends
BIOC analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$1M
↓ 79.0% YoY
Revenue Next Year
$2M
↑ 82.8% YoY
EPS This Year
$-44.33
EPS Next Year
$-5.55
↓ 87.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast BIOC EPS of $-44.33 for the current fiscal year, based on estimates from 1 analysts. The BIOC revenue forecast is $1M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The BIOC stock forecast is supported by two independent data sources: analyst consensus ratings from 3 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus BIOC price target is $0.00 (+0.0% upside), with an analyst consensus of Hold.
The BIOC short-term stock prediction for tomorrow is $0.05 (+0.00%).
Biocept, Inc. trades on NASDAQ under the ticker BIOC. The BIOC stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 33% of covering analysts.
Frequently asked questions
BIOC forecast · 8 questionsAccording to 3 Wall Street analysts, the average 12-month BIOC price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $0.05.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.